1
|
Krieg SM, Trabold R, Plesnila N. Time-Dependent Effects of Arginine-Vasopressin V1 Receptor Inhibition on Secondary Brain Damage after Traumatic Brain Injury. J Neurotrauma 2017; 34:1329-1336. [DOI: 10.1089/neu.2016.4514] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sandro M. Krieg
- Laboratory of Experimental Neurosurgery, LMU Munich, Munich, Germany
| | - Raimund Trabold
- Laboratory of Experimental Neurosurgery, LMU Munich, Munich, Germany
- Department of Neurosurgery, LMU Munich, Munich, Germany
| | - Nikolaus Plesnila
- Laboratory of Experimental Neurosurgery, LMU Munich, Munich, Germany
- Institute for Stroke and Dementia Research, LMU Munich, Munich, Germany
- Munich Cluster for Systems Neurology, LMU Munich, Munich, Germany
| |
Collapse
|
2
|
Cintra EDA, Maciel JA, Araújo S, Castro MD, Martins EF, Falcão ALE, Sardinha LAC, Terzi RGG, Dragosavac D, Cardoso APD, Oliveira RARA. Vasopressin serum levels in patients with severe brain lesions and in brain-dead patients. ARQUIVOS DE NEURO-PSIQUIATRIA 2004; 62:226-32. [PMID: 15235722 DOI: 10.1590/s0004-282x2004000200007] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
INTRODUCTION: Patients with severe brain lesions (SBL) and brain-dead patients (BD) frequently present with vasopressin (AVP) secretion disorders. OBJECTIVE: To evaluate AVP serum levels in SBL and BD patients. DESIGN: Prospective, open label, observational trial. SETTING: A general teaching hospital. METHOD: Three groups of adult subjects (age> 18y) of both sexes were included in this study: control group: 29 healthy volunteers; SBL group: 17 patients with Glasgow Coma Scale (GCS)< 8; and BD group: 11 brain-dead patients. Samples of venous blood were collected in the morning at rest from healthy volunteers and at 8 hourly intervals over a period of 24h from SBL and BD patients for AVP determinations. Concomitantly, some clinical and laboratorial variables were also recorded. RESULTS: AVP serum levels (pg/ml) were [mean (SD); median]: control [2.2(1.1); 2.0]; SBL [5.7(6.3); 2.9]; and BD [2.6(1.0); 2.8]. AVP serum levels varied greatly in SBL patients, but without statistically significant difference in relation to the other groups (p=0.06). Hypotension (p=0.02), hypernatremia (p=0.0001), serum hyperosmolarity (p=0.0001) and urinary hypoosmolarity (p=0.003) were outstanding in BD patients when compared with SBL. CONCLUSIONS: The AVP serum levels did not demonstrate significant statistical difference between the groups, only showing a greater variability in SBL patients (manifested as serum spike levels). Hypernatremia and hyperosmolarity were present in BD patients, indicating a failure of the hypothalamic-pituitary system in AVP production and release.
Collapse
Affiliation(s)
- Eliane de Araújo Cintra
- Department of Neurology, Faculty of Medical Sciences, State University of CampinasRecife, PE, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|